Document Detail

Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury.
MedLine Citation:
PMID:  16960983     Owner:  NLM     Status:  MEDLINE    
Synthetic high density lipoproteins (sHDL) are discoidal lipoprotein particles made of an apolipoprotein and a phospholipid, which mimic most, if not all, of the atheroprotective properties of plasma HDL, including stimulation of reverse cholesterol transport (RCT), prevention of endothelial dysfunction, and inhibition of lipid oxidation. sHDL are currently under development as a novel treatment for atherosclerotic cardiovascular disease. A number of preclinical studies have demonstrated the ability of single or multiple injections of sHDL to induce the regression of atherosclerotic plaques and prevent arterial restenosis. In the first phase II trial in patients with acute coronary syndromes, a short-term treatment with sHDL containing the disulfide-linked dimer of the apolipoprotein A-IMilano variant (A-IM/A-IM) caused a remarkable reduction of atheroma volume. sHDL also display a direct cardioprotective activity in ex vivo and in vivo models of myocardial ischemia/reperfusion (I/R) injury, and may become a useful adjunctive therapy to improve clinical outcomes in patients with acute coronary syndromes or undergoing coronary procedures.
Laura Calabresi; Monica Gomaraschi; Giuseppe Rossoni; Guido Franceschini
Related Documents :
10511283 - High risk strategies for atherosclerosis.
12925453 - Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis o...
16217993 - Left ventricular endocardial calcification in a patient with myeloproliferative disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  111     ISSN:  0163-7258     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-07     Completed Date:  2006-12-04     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  836-54     Citation Subset:  IM    
Center E. Grossi Paoletti, Department of Pharmacological Sciences, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / pharmacology
Apolipoprotein A-I / blood
Atherosclerosis / prevention & control
Cholesterol / metabolism
Endothelium, Vascular / drug effects,  physiology
Lipoproteins, HDL / blood,  pharmacology,  physiology,  therapeutic use*
Lipoproteins, LDL / metabolism
Myocardial Reperfusion Injury / drug therapy*
Reg. No./Substance:
0/Antioxidants; 0/Apolipoprotein A-I; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  5-hydroxytryptamine receptors in the human cardiovascular system.
Next Document:  Introduction to the newborn screening fact sheets.